Business Description
TheraCryf PLC
ISIN : GB00BSVYN304
Description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.77 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -13.54 | |||||
| Beneish M-Score | 8.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 14.8 | |||||
| 3-Year EPS without NRI Growth Rate | 15.1 | |||||
| 3-Year FCF Growth Rate | 18.1 | |||||
| 3-Year Book Growth Rate | -40.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 7.76 | |||||
| 6-1 Month Momentum % | -87.5 | |||||
| 12-1 Month Momentum % | -95.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.19 | |||||
| Quick Ratio | 4.19 | |||||
| Cash Ratio | 2.77 | |||||
| Days Sales Outstanding | 427.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -898.99 | |||||
| Net Margin % | -792.17 | |||||
| FCF Margin % | -760.35 | |||||
| ROE % | -81.01 | |||||
| ROA % | -69.27 | |||||
| ROIC % | -590.15 | |||||
| 3-Year ROIIC % | -176.94 | |||||
| ROC (Joel Greenblatt) % | -1028.9 | |||||
| ROCE % | -91.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7 | |||||
| PB Ratio | 0.78 | |||||
| EV-to-EBIT | -0.28 | |||||
| EV-to-Forward-EBIT | -0.71 | |||||
| EV-to-EBITDA | -0.28 | |||||
| EV-to-Forward-EBITDA | -0.76 | |||||
| EV-to-Revenue | 2.48 | |||||
| EV-to-Forward-Revenue | 2.36 | |||||
| EV-to-FCF | -0.33 | |||||
| Earnings Yield (Greenblatt) % | -357.76 | |||||
| FCF Yield % | -100.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TheraCryf PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.459 | ||
| EPS (TTM) (€) | -0.013 | ||
| Beta | 0.79 | ||
| Volatility % | 122.7 | ||
| 14-Day RSI | 7.76 | ||
| 14-Day ATR (€) | 0.000036 | ||
| 20-Day SMA (€) | 0.0005 | ||
| 12-1 Month Momentum % | -95.45 | ||
| 52-Week Range (€) | 0.0005 - 0.0125 | ||
| Shares Outstanding (Mil) | 427.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TheraCryf PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TheraCryf PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
TheraCryf PLC Frequently Asked Questions
What is TheraCryf PLC(FRA:8EV)'s stock price today?
The current price of FRA:8EV is €0.00. The 52 week high of FRA:8EV is €0.01 and 52 week low is €0.00.
When is next earnings date of TheraCryf PLC(FRA:8EV)?
The next earnings date of TheraCryf PLC(FRA:8EV) is 2024-10-31 Est..
Does TheraCryf PLC(FRA:8EV) pay dividends? If so, how much?
TheraCryf PLC(FRA:8EV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers